Uveal Melanoma Therapeutics Market: By Disease Type (Choroidal Melanomas, Iris Melanomas, and Ciliary Body Melanomas), By Treatment Type (Chemotherapy, Immunotherapy, and Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Uveal Melanoma Therapeutics Market size was valued at USD 1.21 billion in 2022 and is poised to grow at a CGAR of 5.4% from 2023-2029. Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea. Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II  study of Nivolumab in combination with Ipilimumab for Uveal Melanoma

 

 

Uveal Melanoma Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.4%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Uveal Melanoma Therapeutics Market Dynamics

Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.

Key Features of the Reports

  • The uveal melanoma therapeutics market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Uveal Melanoma Therapeutics Market Segmentation

By Disease Type
  • Choroidal Melanomas
    • Small Melanomas
    • Medium-sized Melanomas
    • Large Melanomas
  • Iris melanomas
  • Ciliary Body Melanomas
By Choroidal Melanomas
  • Chemotherapy
    • Methotrexate
    • Others
  • Immunotherapy Drugs
    • Pembrolizumab
    • Ipilimumab
    • Others
  • Targeted Drugs
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The uveal melanoma therapeutics market size was valued at USD 1.21 billion in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The uveal melanoma therapeutics market key players are Eli Lilly & Co. (U.S), Novartis AG (Switzerland), AstraZeneca plc (UK), Pfizer, Inc. (U.S), Merck (U.S), Roche (Switzerland), Amgen (U.S), Bayer (Germany), Spectrum Pharmaceuticals, Inc. (U.S)

1. Executive Summary
2.  Global Uveal Melanoma Therapeutics Market Introduction 
2.1. Global Uveal Melanoma Therapeutics Market  - Taxonomy
2.2. Global Uveal Melanoma Therapeutics Market  - Definitions
2.2.1. By Disease Type
2.2.2. By Choroidal Melanomas
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Uveal Melanoma Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Uveal Melanoma Therapeutics Market  By Disease Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Choroidal Melanomas
4.1.1. Small Melanomas
4.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.1.3. Market Opportunity Analysis 
4.1.2. Medium-sized Melanomas
4.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.2.3. Market Opportunity Analysis 
4.1.3. Large Melanomas
4.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.3.3. Market Opportunity Analysis 
4.2. Iris melanomas
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.3. Market Opportunity Analysis 
4.3. Ciliary Body Melanomas
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.3.3. Market Opportunity Analysis 
5. Global Uveal Melanoma Therapeutics Market  By Choroidal Melanomas, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Chemotherapy
5.1.1. Methotrexate
5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.1.3. Market Opportunity Analysis 
5.1.2. Others
5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.2.3. Market Opportunity Analysis 
5.2. Immunotherapy Drugs
5.2.1. Pembrolizumab
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.1.3. Market Opportunity Analysis 
5.2.2. Ipilimumab
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.2.3. Market Opportunity Analysis 
5.2.3. Others
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3.3. Market Opportunity Analysis 
5.3. Targeted Drugs
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Uveal Melanoma Therapeutics Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacies
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.  Global Uveal Melanoma Therapeutics Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. MEA
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8. North America Uveal Melanoma Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Disease Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1. Choroidal Melanomas
8.1.1.1. Small Melanomas 
8.1.1.2. Medium-sized Melanomas
8.1.1.3. Large Melanomas
8.1.2. Iris melanomas
8.1.3. Ciliary Body Melanomas
8.2. Choroidal Melanomas Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1. Chemotherapy
8.2.1.1. Methotrexate 
8.2.1.2. Others
8.2.2. Immunotherapy Drugs
8.2.2.1. Pembrolizumab
8.2.2.2. Ipilimumab
8.2.2.3. Others
8.2.3. Targeted Drugs
8.3. Distribution Channel Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.4.1. USA
8.4.2. Canada
9. Europe Uveal Melanoma Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Disease Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1. Choroidal Melanomas
9.1.1.1. Small Melanomas 
9.1.1.2. Medium-sized Melanomas
9.1.1.3. Large Melanomas
9.1.2. Iris melanomas
9.1.3. Ciliary Body Melanomas
9.2. Choroidal Melanomas Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1. Chemotherapy
9.2.1.1. Methotrexate 
9.2.1.2. Others
9.2.2. Immunotherapy Drugs
9.2.2.1. Pembrolizumab
9.2.2.2. Ipilimumab
9.2.2.3. Others
9.2.3. Targeted Drugs
9.3. Distribution Channel Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1. Germany
9.4.2. France
9.4.3. Italy
9.4.4. Spain
9.4.5. UK
9.4.6. Rest of Europe
10. Asia Pacific Uveal Melanoma Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Disease Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1. Choroidal Melanomas
10.1.1.1. Small Melanomas 
10.1.1.2. Medium-sized Melanomas
10.1.1.3. Large Melanomas
10.1.2. Iris melanomas
10.1.3. Ciliary Body Melanomas
10.2. Choroidal Melanomas Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1. Chemotherapy
10.2.1.1. Methotrexate 
10.2.1.2. Others
10.2.2. Immunotherapy Drugs
10.2.2.1. Pembrolizumab
10.2.2.2. Ipilimumab
10.2.2.3. Others
10.2.3. Targeted Drugs
10.3. Distribution Channel Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1. China
10.4.2. Japan
10.4.3. South Korea
10.4.4. India
10.4.5. Rest of APAC
11. Latin America Uveal Melanoma Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Disease Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1. Choroidal Melanomas
11.1.1.1. Small Melanomas 
11.1.1.2. Medium-sized Melanomas
11.1.1.3. Large Melanomas
11.1.2. Iris melanomas
11.1.3. Ciliary Body Melanomas
11.2. Choroidal Melanomas Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1. Chemotherapy
11.2.1.1. Methotrexate 
11.2.1.2. Others
11.2.2. Immunotherapy Drugs
11.2.2.1. Pembrolizumab
11.2.2.2. Ipilimumab
11.2.2.3. Others
11.2.3. Targeted Drugs
11.3. Distribution Channel Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Argentina
11.4.4. Rest of Latin America
12. MEA Uveal Melanoma Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Disease Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1. Choroidal Melanomas
12.1.1.1. Small Melanomas 
12.1.1.2. Medium-sized Melanomas
12.1.1.3. Large Melanomas
12.1.2. Iris melanomas
12.1.3. Ciliary Body Melanomas
12.2. Choroidal Melanomas Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1. Chemotherapy
12.2.1.1. Methotrexate 
12.2.1.2. Others
12.2.2. Immunotherapy Drugs
12.2.2.1. Pembrolizumab
12.2.2.2. Ipilimumab
12.2.2.3. Others
12.2.3. Targeted Drugs
12.3. Distribution Channel Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
13.  Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Eli Lilly & Co. (U.S)
13.2.2. Novartis AG (Switzerland)
13.2.3. AstraZeneca plc (UK)
13.2.4. Pfizer, Inc. (U.S)
13.2.5. Merck (U.S)
13.2.6. Roche (Switzerland)
13.2.7. Amgen (U.S)
13.2.8. Bayer (Germany)
13.2.9. Spectrum Pharmaceuticals, Inc. (U.S)
14.  Research Methodology
15.  Key Assumptions and Acronyms
  • Eli Lilly & Co. (U.S)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (UK)
  • Pfizer, Inc. (U.S)
  • Merck (U.S)
  • Roche (Switzerland)
  • Amgen (U.S)
  • Bayer (Germany)
  • Spectrum Pharmaceuticals, Inc. (U.S)

Adjacent Markets